Literature DB >> 25299469

Prediction of the success of thyroid remnant ablation using preablative 99mTc pertechnetate scintigraphy and postablative dual 131I scintigraphy.

Jo Sung Jung1, Sang Mi Lee, Sang Jin Kim, Jiyoun Choi, Sun Wook Han.   

Abstract

OBJECTIVE: The aim of this study was to predict the success of 131I ablation using preablative 99mTc pertechnetate salivary scintigraphy and a postablative dual 131I scan in differentiated thyroid cancer (DTC). PATIENTS AND METHODS: A total of 168 DTC patients who underwent 131I ablation with preablative salivary scintigraphy and a postablative dual (early and delayed) 131I scan were enrolled. For salivary scintigraphy, the thyroid remnant uptake was visually assessed. For the dual 131I scan, the thyroid remnant to background uptake ratios (TBRs) on early and delayed scans were measured and the percentage change in TBR (TBRΔ) was calculated.
RESULTS: Thyroid remnant uptake was seen in 69 (41%) patients on salivary scintigraphy and in 162 (96%) patients on the dual 131I scan. The success rate of ablation was higher in patients with negative remnant uptake on salivary scintigraphy (86%) than in patients with positive remnant uptake (58%, P=0.0001). The success rate of ablation was 100% in patients with no remnant uptake on both salivary scintigraphy and the dual 131I scan. The success rate of ablation was higher in patients with TBRΔ 0 or more than in patients with TBRΔ less than 0, irrespective of remnant uptake on salivary scintigraphy (91 vs. 70%, P=0.03, for patients without remnant uptake on salivary scintigraphy; 74 vs. 48%, P=0.05, for patients with remnant uptake on salivary scintigraphy).
CONCLUSION: The success of thyroid remnant ablation in DTC can be predicted by the presence of remnant uptake on preablative 99mTc pertechnetate scintigraphy and change in remnant uptake on the postablative dual 131I scan.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25299469     DOI: 10.1097/MNM.0000000000000219

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  6 in total

1.  Iodine Uptake Patterns on Post-ablation Whole Body Scans are Related to Elevated Serum Thyroglobulin Levels After Radioactive Iodine Therapy in Patients with Papillary Thyroid Carcinoma.

Authors:  Geum-Cheol Jeong; Minchul Song; Hee Jeong Park; Jung-Joon Min; Hee-Seung Bom; Sang-Geon Cho; Ki Seong Park; Sae-Ryung Kang; Jahae Kim; Ho-Chun Song; Seong Young Kwon
Journal:  Nucl Med Mol Imaging       Date:  2016-05-13

2.  99mTc-pertechnetate-avid metastases from differentiated thyroid cancer are prone to benefit from 131I therapy: A prospective observational study.

Authors:  Min Liu; Li Chai; Qiong Luo; Maomei Ruan; Lingxiao Cheng; Zhongwei Lv; Libo Chen
Journal:  Medicine (Baltimore)       Date:  2017-08       Impact factor: 1.889

3.  99mTc-Pertechnetate Scintigraphy Predicts Successful Postoperative Ablation in Differentiated Thyroid Carcinoma Patients Treated with Low Radioiodine Activities.

Authors:  Luca Giovanella; Gaetano Paone; Teresa Ruberto; Luca Ceriani; Pierpaolo Trimboli
Journal:  Endocrinol Metab (Seoul)       Date:  2019-02-15

4.  The clinical significance of remnant thyroid tissue in thyroidectomized differentiated thyroid cancer patients on 131I-SPECT/CT.

Authors:  Feng Wang; Hui Nie; Wei Li; Rusen Zhang; Wen Li
Journal:  BMC Med Imaging       Date:  2021-05-08       Impact factor: 1.930

Review 5.  Hyperthyroid cats and their kidneys: a literature review.

Authors:  L Yu; L Lacorcia; T Johnstone
Journal:  Aust Vet J       Date:  2022-06-16       Impact factor: 1.343

6.  Optimization of Predictive Performance for the Therapeutic Response Using Iodine Scan-Corrected Serum Thyroglobulin in Patients with Differentiated Thyroid Carcinoma.

Authors:  Su Woong Yoo; Md Sunny Anam Chowdhury; Subin Jeon; Sae-Ryung Kang; Sang-Geon Cho; Jahae Kim; Changho Lee; Young Jae Ryu; Ho-Chun Song; Hee-Seung Bom; Jung-Joon Min; Seong Young Kwon
Journal:  Cancers (Basel)       Date:  2020-01-22       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.